CalciMedica Proposes Public Offering of Common Stock

LA JOLLA, Calif., Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc., a clinical-stage biopharmaceutical company, has announced the initiation of a public offering of its common stock. The company, which trades on Nasdaq under the ticker symbol CALC, focuses on developing innovative therapies that inhibit calcium release-activated calcium (CRAC) channels for treating acute and chronic inflammatory and immunologic diseases.

In this offering, all shares are being sold by CalciMedica. The company also plans to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares. The completion of this offering is contingent upon market conditions and other factors, with no certainty on when or if the offering will be finalized or the exact terms.

Jones is the sole book-running manager for this offering. The public offering is made under a shelf registration statement on Form S-3, which was previously filed with the Securities and Exchange Commission (SEC) on August 11, 2023, and later declared effective on August 18, 2023. A preliminary prospectus supplement and accompanying prospectus detailing the terms of the offering will be filed with the SEC and can be accessed on the SEC's website.

CalciMedica is advancing its lead product candidate, Auxora™, which has shown promising results in various clinical trials. Auxora™ targets CRAC channels to modulate immune responses, potentially offering therapeutic benefits for severe inflammatory and immunologic conditions that currently lack approved treatments.

The company has shared data from a Phase 2b trial (CARPO – NCT04681066) involving patients with AP and SIRS, and has completed a Phase 2 trial (CARDEA – NCT04345614) for patients with COVID-19 pneumonia. Currently, CalciMedica is conducting a Phase 2 trial (KOURAGE – NCT06374797) on patients with AKI and AHRF, with results expected in 2025. Additionally, they are supporting an ongoing Phase 1/2 trial (CRSPA – NCT04195347) for patients with AIPT, with data anticipated in 2025.

Founded by researchers from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, CalciMedica is headquartered in La Jolla, California. The company's proprietary technologies and focus on CRAC channel inhibition position it at the forefront of developing new treatments for challenging inflammatory and immunologic diseases.